UPDATE: FDA Approves Tradjenta™ Tablets for the Treatment of Type 2 Diabetes (LLY)

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company LLY today announced that the U.S. Food and Drug Administration has approved Tradjenta™ tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA can be used as monotherapy or in combination with other commonly prescribed medications for type 2 diabetes — metformin, sulfonylurea or pioglitazone — and demonstrated reductions in hemoglobin A1C levels up to 0.7 percent. A1C is measured in people with diabetes to provide an index of blood sugar control for the previous two to three months. TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in combination with insulin.